Liquid Biopsy Predicts Response in Patients with Advanced Lung Cancer
Johns Hopkins researchers are pioneering the use of a “liquid biopsy” to predict which patients with advanced lung cancers are responding to immunotherapies and which patients may develop immune-related side effects several months later.
